300463.SZ
Maccura Biotechnology Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 9.14
−2.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.1B | 2.2B | 2.5B | 2.9B | 3.6B |
| Cost of Revenue | 870.8M | 890.5M | 1.1B | 1.3B | 1.7B |
| Gross Profit | 1.3B | 1.3B | 1.4B | 1.6B | 2.0B |
| Operating Expenses | |||||
| R&D Expense | 327.0M | 317.9M | 323.2M | 324.2M | 273.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 231.8M | 219.7M | 165.1M | 184.2M | 155.8M |
| Selling & Marketing Expense | 685.7M | 684.3M | 646.8M | 652.4M | 629.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.3B | 1.3B | 1.2B | 1.2B | 1.1B |
| Cost and Expenses | 2.2B | 2.2B | 2.3B | 2.5B | 2.8B |
| Operating Income (EBIT) | (85.2M) | (60.8M) | 170.0M | 331.1M | 817.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (120.6M) | (99.5M) | 124.7M | 305.4M | 789.1M |
| Income Tax Expense | (60.2M) | (58.0M) | 5.9M | 689.9K | 87.4M |
| Bottom Line | |||||
| Net Income | (50.8M) | (35.8M) | 126.8M | 312.6M | 708.2M |
| Earnings from Cont. Ops | (60.3M) | (41.5M) | 118.8M | 304.7M | 701.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (50.8M) | (35.8M) | 126.8M | 312.6M | 708.2M |
| Per Share | |||||
| Basic EPS | (CN¥0.08) | (CN¥0.06) | CN¥0.21 | CN¥0.51 | CN¥1.17 |
| Diluted EPS | (CN¥0.08) | (CN¥0.06) | CN¥0.21 | CN¥0.51 | CN¥1.17 |
| Revenue Per Share | CN¥3.54 | CN¥3.59 | CN¥4.20 | CN¥4.76 | CN¥5.97 |
| Shares | |||||
| Basic Shares Outstanding | 603.1M | 604.2M | 606.4M | 608.7M | 603.9M |
| Diluted Shares Outstanding | 603.1M | 604.2M | 606.4M | 608.7M | 603.9M |
| Profitability Metrics | |||||
| EBITDA | — | 298.6M | 494.9M | 630.8M | 1.1B |
| D&A | — | 359.3M | 324.9M | 299.7M | 256.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026